Radiofrequenzablation mit dem HALO-System in der Behandlung des Barrett-Ösophagus

Zusammenfassung

In den letzten Jahren hat sich die Radiofrequenzablation mit dem HALO-System in der Behandlung des Barrett-Ösophagus etablieren können. Das HALO-System besteht aus der Kombination eines zirkumferenziellen Ablationskatheters mit auf einem Ballon angebrachten bipolaren Elektrodenringen und eines fokalen Ablationskatheters mit bipolaren Elektroden, die auf einer flexiblen Plattform an der Spitze des Endoskops befestigt werden. Die Radiofrequenzablation ist ein wertvolles therapeutisches Verfahren in Kombination mit einer initial durchgeführten endoskopischen Resektion bei ausgewählten Patienten mit frühen Barrett-Neoplasien. Klinische Studien konnten zeigen, dass die Radiofrequenzablation ein effektives und sicheres Verfahren mit niedriger Komplikationsrate und dauerhaftem Therapieerfolg darstellt, die Funktionsfähigkeit des Ösophagus bewahrt, technisch gut anwendbar ist und in der Regel zur Regeneration von neuem Plattenepithel des Ösophagus ohne präexistente genetische Anomalien führt.

Abstract

In recent years radiofrequency ablation using the HALO system in the treatment of Barrett’s oesophagus has become established. The HALO system consists of a circumferential ablation using a balloon-based electrode and a focal ablation using an endoscope-mounted bipolar electrode on an articulated platform. In combination with prior endoscopic resection radiofrequency ablation is a valuable therapeutic technique in selected patients with early Barrett’s neoplasia. Clinical trials demonstrate that radiofrequency ablation is highly effective and durable, has low complication rates, preserves the functional integrity of the oesophagus, is easy to apply and the regenerating neosquamous epithelium is free of pre-existing oncogenetic alterations.

Schlüsselwörter

Barrett-Ösophagus - Ösophaguskarzinom - GERD

Key words

Barrett’s oesophagus - Oesophageal cancer - GERD

• Literatur

• 1 Sharma P, Dent J, Armstrong D et al. The development and validation of an endoscopic grading system for Barrett‘ esophagus: the Prague C & M criteria. Gastroenterology 2006; 131: 1392-1399
• 2 Curvers WL, Bergman JJ. Multimodality imaging in Barrett‘s esophagus: looking longer, seeing better, and recognizing more. Gastroenterology 2008; 135: 297-279
• 3 Longcroft-Wheaton G, Duku M, Mead R et al. Acetic acid spray is an effective tool for the endoscopic detection of neoplasia in patients with Barrett’s esophagus. Clin Gastroenterol Hepatol 2010; 8: 843-847
• 4 Curvers WL, Baak L, Kiesslich R et al. Chromoendoscopy and narrow-band imaging compared with high-resolution magnification endoscopy in Barrett’s esophagus. Gastroenterology 2008; 134: 670-679
• 5 Mannath J, Subramanian V, Hawkey CJ et al. Narrow band imaging for characterization of high-grade dysplasia and specialized intestinal metaplasia in Barrett’s esophagus: a meta-analysis. Endoscopy 2010; 42: 351-359
• 6 Curvers WL, Singh R, Wong KeeSong LM et al. Endoscopic trimodal imaging for detection of early neoplasia in Barrett’s oesophagus; a multi-centre feasibility study using high-resolution endoscopy, autofluorescence imaging and narrow band imaging incorporated in one endoscopy system. Gut 2008; 57: 167-172
• 7 Curvers WL, Herrero LA, Wallace MB et al. Endoscopic tri-modal imaging is more effective than standard endoscopy in identifying early-stage neoplasia in Barrett’s esophagus. Gastroenterology 2010; 139: 1106-1114
• 8 Curvers WL, van Vilsteren FG, Baak LC et al. Endoscopic trimodal imaging versus standard video endoscopy for detection of early Barrett’s neoplasia: a multicenter, randomized, crossover study in general practice. Gastrointest Endosc 2011; 73: 195-203
• 9 Sharma P, Meining AR, Coron E et al. Real-time increased detection of neoplastic tissue in Barrett’s esophagus with probe-based confocal laser endomicroscopy: final results of an international multicenter, prospective, randomized, controlled trial. Gastrointest Endosc 2011; 74: 465-472
• 10 Pech O, Gossner L, Manner H et al. Prospective evaluation of the macroscopic types and location of early Barrett’s neoplasia in 380 lesions. Endoscopy 2007; 39: 588-593
• 11 Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 2011; 14: 101-112
• 12 Endoscopic Classification Review Group. Update on the paris classification of superficial neoplastic lesions in the digestive tract. Endoscopy 2005; 37: 570-578
• 13 Pouw RE, Bergmann JJ. Endoscopic resection of early oesophageal and gastric neoplasia. Best Pract Res Clin Gastroenterol 2008; 22: 929-943
• 14 Soehendra N, Seewald S, Groth S et al. Use of modified multiband ligator facilitates circumferential EMR in Barrett’s esophagus. Gastrointest Endosc 2006; 63: 847-852
• 15 Alvarez Herrero L, Pouw RE, van Vilsteren FG et al. Safety and efficacy of multiband mucosectomy in 1060 resections in Barrett’s esophagus. Endoscopy 2011; 43: 177-183
• 16 Gondrie JJ, Pouw RE, Sondermeijer CM et al. Stepwise circumferential and focal ablation of Barrett’s esophagus with high-grade dysplasia: results of the first prospective series of 11 patients. Endoscopy 2008; 40: 359-369
• 17 Gondrie JJ, Pouw RE, Sondermeijer CM et al. Effective treatment of early Barrett’s neoplasia with stepwise circumferential and focal ablation using the HALO system. Endoscopy 2008; 40: 370-379
• 18 Pouw RE, Sharma VK, Bergmann JJ et al. Radiofrequency ablation for total Barrett’s eradication: a description of the endoscopic technique, its clinical results and future prospects. Endoscopy 2008; 40: 1033-1040
• 19 Choi YN, Willekens H, Coremans G et al. Short term side effects after radiofrequency ablation. Are we ready to ablate non-dsyplastic Barrett?. Gut 2011; 60 (Suppl. 03) A59
• 20 Pech O, Behrens A, May A et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett’s oesophagus. Gut 2008; 57: 1200-1206
• 21 Manner H, May A, Pech O et al. Early Barrett’s carcinoma with „low-risk” submucosal invasion: long-term results of endoscopic resection with a curative intent. Am J Gastroenterol 2008; 103: 2589-2597
• 22 Messman H, Ell C, Fein M et al. Gastroösophageale Refluxkrankheit – Ergebnisse einer evidenzbasierten Konsensuskonferenz der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten. Themenkomplex VI: Barrett-Ösophagus. Z Gastroenterol 2005; 43: 184-190
• 23 Wang KK, Sampliner RE Practice Parameters Committee of the American College of Gastroenterology Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus. Am J Gastroenterol 2008; 103: 788-797
• 24 Spechler SJ, Sharma P et al. American Gastroenterological Association American Gastroenterological Association medical position statement on the management of Barrett‘s esophagus. Gastroenterology 2011; 140: 1084-1091
• 25 Stefanidis D, Hope WW, Kohn GP et al. SAGES Guidelines Committee. Guidelines for surgical treatment of gastroesophageal reflux disease. Surg Endosc 2010; 24: 2647-2669
• 26 Centre for Clinical Practice at NICE (UK). Barrett’s Oesophagus: Ablative therapy for the treatment of Barrett’s oesophagus. National Institute for Health and Clinical Excellence (UK); 2010 August
• 27 Moss A, Bourke MJ, Hourigan LF et al. Endoscopic resection for Barrett’s high-grade dysplasia and early esophageal adenocarcinoma: an essential staging procedure with long-term therapeutic benefit. Am J Gastroenterol 2010; 105: 1276-1283
• 28 Peter FP, Brakenhoff KP, Curvers WL et al. Histologic evaluation of resection specimens obtained at 293 endoscopic resections in Barrett’s esophagus. Gastrointest Endosc 2008; 67: 604-609
• 29 Pouw RE, Wirths K, Eisendrath P et al. Efficacy of radiofrequency ablation combined with endoscopic resection for Barrett’s esophagus with early neoplasia. Clin Gastroenterol Hepatol 2010; 8: 23-29
• 30 Pouw RE, Bergmann JJ, Bisschops R et al. Radiofrequency ablation combined with endoscopic resection, for eradication of Barrett’s oesophagus containing early neoplasia in 130 patients: results of a european multicenter study (EURO II). Gut 2011; 60 (Suppl. 03) A5
• 31 Skacel M, Petras RE, Gramlich TL et al. The diagnosis of low-grade-dysplasia in Barrett’s esophagus and it implications for disease progression. Am J Gastroenterol 2000; 95: 3383-3387
• 32 Curvers WL, ten Kate FJ, Krishnadath KK et al. Low-grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated. Am J Gastroenterol 2010; 7: 1523-1530
• 33 Baak JP, ten Kate FJ, Offerhaus GJ et al. Routine morphometrical analysis can improve reproducibility of dysplasia grade in Barrett’s oesophagus surveillance biopsies. J Clin Pathol 2002; 55: 910-916
• 34 Sharma VK, Kim HJ, Das A et al. A prospective pilot trial of ablation of Barrett’s esophagus with low-grade-dysplasia using stepwise circumferential and focal ablation (HALO system). Endoscopy 2008; 40: 380-387
• 35 Shaheen NJ, Sharma P, Overholt BF et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med 2009; 22: 2277-2288
• 36 Fleischer DE, Odze R, Overholt BF et al. The case of endoscopic treatment of non-dysplastic and low-grade dysplastic Barrett’s esophagus. Dig Dis Sci 2010; 7: 1918-1931
• 37 Sharma P, Faulk GW, Weston AP et al. Dysplasia and cancer in a large multicenter cohort of patients with Barrett’s esophagus. Clin Gastroenterol Hepatol 2006; 4: 566-572
• 38 de Jonge PJ, van Blankenstein M, Looman CW et al. Risk of malignant progression in patients with Barrett’s oesophagus: a Dutch nationwide cohort study. Gut 2010; 59: 1030-1036
• 39 Wani S, Falk G, Hall M et al. Patients with nondysplastic Barrett’s esophagus have low risks for developing dysplasia or eosphageal adenocarcinoma. Clin Gastroenterol Hepatol 2011; 9: 220-227
• 40 Hvid-Jensen F, Pedersen L, Drewes AM et al. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med 2011; 365: 1375-1383
• 41 Pouw RE, Gondrie JJ, Curvers WL et al. Succesful ballon-based radiofrequency ablation of a widespread early squamous cell carcinoma and high-grade dysplasia of the esophagus: a case report. Gastrointest Endosc 2008; 68: 537-541
• 42 van Vilsteren FG, Alvarez Herrero L, Pouw RE et al. Radiofrequency ablation for the endoscopic eradication of esophageal squamous high grade intraepithelial neoplasia and mucosal squamous cell carcinoma. Endoscopy 2011; 43: 282-290
• 43 Becker V, Bajbouj M, Schmid RM et al. Multimodal endoscopic therapy for multifocal intraepithelial neoplasia and superficial esophageal squamous cell carcinoma – a case series. Endoscopy 2011; 43: 360-364
• 44 Bergman JJ, Zhang YM, He S et al. Outcomes from a prospective trial of endoscopic radiofrequency ablation of early squamous cell neoplasia of the esophagus. Gastrointest Endosc 2011; 74: 1181-1190
• 45 Gross SA, Al-Haddad M, Gill KR et al. Endoscopic mucosal ablation for the treatment of gastric antral vascular ectasia with the HALO90 system: a pilot study. Gastrointest Endosc 2008; 67: 324-327
• 46 Zhou C, Adler DC, Becker L et al. Effective treatment of chronic proctitis using radiofrequency ablation. Therap Adv Gastroenterol 2009; 2: 149-156
• 47 Nikfarjam M, Faulx A, Laughinghouse M et al. Feasibility of radiofrequency ablation for the treatment of chronic radiation proctitis. Surg Innov 2010; 17: 92-94
• 48 Sharma VK, Wang KK, Overholt BF et al. Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett’s esophagus: 1-year follow-up of 100 patients. Gastrointest Endosc 2007; 65: 185-195
• 49 Fleischer DE, Overholt BF, Sharma VK et al. Endoscopic ablation of Barrett’s esophagus: a multicenter study with 2.5-year follow-up. Gastrointest Endosc 2008; 68: 867-876
• 50 Fleischer DE, Overholt BF, Sharma VK et al. Endoscopic radiofrequency ablation for Barrett’s esophagus: 5-year outcomes from a prospective multicenter trial. Endoscopy 2010; 10: 781-789
• 51 Shaheen NJ, Overholt BF, Sampliner RE et al. Durability of radiofrequency ablation in Barrett’s esophagus with dysplasia. Gastroenterology 2011; 141: 460-468
• 52 Ganz RA, Overholt BF, Sharma VK et al. Circumferential ablation of Barrett’s esophagus that contains high-grade dsyplasia: a U. S. Multicenter Registry. Gastrointest Endosc 2008; 68: 35-40
• 53 Herrero LA, van Vilsteren FG, Pouw RE et al. Endoscopic radiofrequency ablation combined with endoscopic resection for early neoplasia in Barrett’s esophagus longer than 10cm. Gastrointest Endosc 2011; 73: 682-690
• 54 Peters FP, Kara MA, Rosmolen WD et al. Stepwise radical endoscopic resection is effective for complete removal of Barrett’s esophagus with early neoplasia: a prospective study. Am J Gastroenterol 2006; 101: 1449-1457
• 55 Pouw RE, Peters FP, Sempoux C et al. Stepwise radical endoscopic resection for Barrett’s esophagus with early neoplasia: report on a Brussels’ cohort. Endoscopy 2008; 40: 892-898
• 56 Chennat J, Konda VJ, Ross AS et al. Complete Barrett’s eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma – an American single-center experience. Am J Gastroenterol 2009; 104: 2684-2692
• 57 Pouw RE, Seewald S, Gondrie JJ et al. Stepwise radical endoscopic resection for eradication of Barrett’s oesophagus with early neoplasia in a cohort of 169 patients. Gut 2010; 59: 1169-1177
• 58 van Vilsteren FG, Pouw RE, Seewald S et al. Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett’s oesophagus with high-grade dysplasia of early cancer: a multicentre randomised trial. Gut 2011; 60: 765-773
• 59 Beaumont H, Gondrie JJ, McMahon BP et al. Stepwise radiofrequency ablation of Barrett’s esophagus preserves esophageal inner diameter, compliance, and motility. Endoscopy 2009; 41: 2-8
• 60 Overholt BF, Panjehpour M, Halberg DL. Photodynamic therapy for Barrett’s esophagus with dysplasia and/or early stage carcinoma: long-term results. Gastrointest Endosc 2003; 58: 183-188
• 61 Overholt BF, Wang KK, Burdick JS et al. Five-year efficacy and safety of photodynamic therapy with photofrin in Barrett’s high-grade dysplasia. Gastrointest Endosc 2007; 66: 460-468
• 62 Pech O, Gossner L, May A et al. Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett’s cancer and high-grade intraepithelial neoplasia. Gastrointest Endosc 2005; 62: 24-30
• 63 Wang KK, Lutzke L, Borkenhagen W et al. Photodynamic therapy for Barrett’s esophagus: does light still have a role?. Endoscopy 2008; 40: 1021-1025
• 64 Waxman I, Konda VJ. Mucosal ablation of Barrett’s esophagus. Nat Rev Gastroenterol Hepatol 2009; 6: 393-401
• 65 van Laethem JL, Cremer M, Peny MO et al. Eradication of Barrett’s mucosa with argon plasma coagulation and acid suppression: immediate and mid term results. Gut 1998; 43: 747-751
• 66 Dulai GS, Jensen DM, Cortina G et al. Randomized trial of argon plasma coagulation vs. multipolar electrocoagulation for ablation of Barrett’s esophagus. Gastrointest Endosc 2005; 61: 232-240
• 67 Manner H, May A, Miehlke S et al. Ablation of nonneoplastic Barrett’s mucosa using argon plasma coagulation with concomitant esomeprazole therapy: a prospective multicenter evaluation. Am J Gastroenterol 2006; 101: 1762-1769
• 68 Sharma P, Wani S, Weston AP et al. A randomized controlled trial of ablation of Barrett’s oesophagus with multipolar electrocoagulation versus argon plasma coagulation in combination with acid suppression: long term results. Gut 2006; 55: 1233-1239
• 69 Mörk H, Al-Taie O, Berlin F et al. High recurrence rate of Barrett’s epithelium during long-term follow-up after argon plasma coagulation. Scand J Gastroenterol 2007; 42: 23-27
• 70 Attwood SE, Lewis CJ, Caplin S et al. Argon beam plasma coagulation as therapy for high-grade dysplasia in Barrett’s esophagus. Clin Gastroenterol Hepatol 2003; 1: 258-263
• 71 Pereira-Lima JC, Busnello JV, Saul C et al. High power setting argon plasma coagulation for the eradication of Barrett’s esophagus. Am J Gastroenterol 2000; 95: 1661-1668
• 72 Ragunath K, Krasner N, Raman VS et al. Endoscopic ablation of dysplastic Barrett’s oesophagus comparing argon plasma coagulation and photodynamic therapy: a randomized prospective trial assessing efficacy and cost-effectivness. Scand J Gastroenterol 2005; 40: 750-758
• 73 Dumont JA, Greenwald BD. Argon plasma coagulation, bipolar cautery, and cryotherapy: ABC’s of ablative techniques. Endoscopy 2008; 40: 1026-1032
• 74 Shaheen NJ, Peery AF, Overholt BF et al. Biopsy depth after radiofrequency ablation of dysplastic Barrett’s esophagus. Gastrointest Endosc 2010; 72: 490-496
• 75 Odze RD, Lauwers GY. Histopathology of Barrett’s esophagus after ablation and endoscopic mucosal resection therapy. Endoscopy 2008; 40: 1008-1015
• 76 Gray NA, Odze RD, Spechler SJ. Buried Metaplasia after endoscopic ablation of Barrett’s esophagus: a systematic review. Am J Gastroenterol 2011; 106: 1899-1908
• 77 Pouw RE, Gondrie JJ, Rygiel AM et al. Properties of the neosquamous epithelium after radiofrequency ablation of Barrett’s esophagus containing neoplasia. Am J Gastroenterol 2009; 104: 1366-1373
• 78 Vaccaro BJ, Gonzalez S, Poneros JM et al. Detection of intestinal metaplasia after successful eradication of Barrett’s esophagus with radiofrequency ablation. Dig Dis Sci 2011; 56: 1996-2000